Abbott (NYSE:ABT) touted results today from real-world use data for its FreeStyle Libre blood glucose monitoring system. The data showed that people using its FreeStyle Libre system to monitor their glucose levels spend less time in hypoglycemia or hyperglycemia and have improved average glucose levels.
More than 50,000 diabetes patients using the FreeStyle Libre system checked their glucose levels 16 times a day, on average, according to the data.
Get the full story at our sister site, Drug Delivery Business News.